Incyte's 'IDO' Cancer Immunotherapy Causes Investor Scrum at ASCO '14

It's me again, still reporting from the American Society of Clinical Oncology (ASCO) annual meeting. We just got our first look at the clinical activity of Incyte's (INCY) immuno-oncology candidate INCB024360 ('360) dosed at 50 mg and combined with Bristol-Myers Squibb's  (BMY) Yervoy in melanoma patients. The Wall Street scrum around the Incyte poster was insane. 


Oh yeah, you're probably interesting in hearing about the data. Four immunotherapy-naive melanoma patients dosed with 50 mg of '360 plus Yervoy yielded 1 complete response and 1 partial response for an overall response rate of 50%. A third patient reported stable disease so the disease control rate was 75%. The Incyte press release and poster can be found here

Seeing a complete response is always a good sign, so while the number of patients treated in the 50 mg cohort is small, there's enough clinical activity here to justify running new combination studies of '360 and the PD-1 inhibitors from Bristol, Merck (MRK) and others. 

We last saw data on '360 at the 25 mg dose when the ASCO abstracts were released in mid May.

Incyte shares rebounded big time when the '360 data were announced this afternoon.


INCY Price ChartINCY Price data by YCharts

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Investing

3 Best Investing Opportunities Right Now in Closed-End Funds

3 Best Investing Opportunities Right Now in Closed-End Funds

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

When Is It 'Worth It' to Work With a Financial Advisor?

When Is It 'Worth It' to Work With a Financial Advisor?

Amazon, Microsoft and Google Face Backlash over ICE, Military Deals

Amazon, Microsoft and Google Face Backlash over ICE, Military Deals

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In